GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lombard Medical Technologies PLC (LSE:LMT) » Definitions » Total Liabilities

Lombard Medical Technologies (LSE:LMT) Total Liabilities : £5.09 Mil (As of Dec. 2012)


View and export this data going back to . Start your Free Trial

What is Lombard Medical Technologies Total Liabilities?

Lombard Medical Technologies's Total Liabilities for the quarter that ended in Dec. 2012 was £5.09 Mil.

Lombard Medical Technologies's quarterly Total Liabilities increased from Dec. 2010 (£2.58 Mil) to Dec. 2011 (£2.96 Mil) and increased from Dec. 2011 (£2.96 Mil) to Dec. 2012 (£5.09 Mil).

Lombard Medical Technologies's annual Total Liabilities increased from Dec. 2010 (£2.58 Mil) to Dec. 2011 (£2.96 Mil) and increased from Dec. 2011 (£2.96 Mil) to Dec. 2012 (£5.09 Mil).


Lombard Medical Technologies Total Liabilities Historical Data

The historical data trend for Lombard Medical Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lombard Medical Technologies Total Liabilities Chart

Lombard Medical Technologies Annual Data
Trend Sep02 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.67 2.13 2.58 2.96 5.09

Lombard Medical Technologies Semi-Annual Data
Sep02 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.67 2.13 2.58 2.96 5.09

Lombard Medical Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lombard Medical Technologies's Total Liabilities for the fiscal year that ended in Dec. 2012 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.086+(0+-8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.09

Total Liabilities=Total Assets (A: Dec. 2012 )-Total Equity (A: Dec. 2012 )
=9.241-4.155
=5.09

Lombard Medical Technologies's Total Liabilities for the quarter that ended in Dec. 2012 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.086+(0+-8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.09

Total Liabilities=Total Assets (Q: Dec. 2012 )-Total Equity (Q: Dec. 2012 )
=9.241-4.155
=5.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lombard Medical Technologies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lombard Medical Technologies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Lombard Medical Technologies (LSE:LMT) Business Description

Traded in Other Exchanges
N/A
Address
Lombard Medical Technologies PLC is engaged in the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through the group's own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. The principal product, the AorfixT AAA stent graft has European CE mark approval for use in patients with high-angle-neck aneurysms of up to 90 degrees. The group has operations in United Kingdom and United States of America.